How adding Isolcork to your building could save you thousands — or even millions

Cutting Costs

Photo courtesy of Isolcork

As temperatures continue to rise and electricity costs follow suit, companies and homeowners are keen on finding ways to cut costs while improving their energy efficiency.

That's where Isolcork comes in. This top-of-the-line, multi-purpose, cork-based finish is sustainable, aesthetically pleasing, insulating, and durable, both for maintenance and new construction projects.

And the best part is that it's applied to the exterior only, meaning there's no need to pause or rearrange what's happening inside — whether that's manufacturing or everyday life — while the building's envelope is improved.

Isolcork has specialized in sustainable cork for the construction, operational, and maintenance industry since 2010, and is now available for residential use as well. Its products have been commercialized in 14 countries in both Europe and Latin America and used on more than 10,000 projects worldwide, including 25-plus in Arizona and Texas. All Isolcork lab tests have been conducted in U.S. labs under ASTM.

There are two options:

  • Spray cork: A blend of premium granulated cork particles combined with high-grade water-based resins, mineral fillers, stabilizers, and additives. (This video demonstration goes into more detail.)
  • Rubber top: Sprayable waterproofing membrane with rubber and nanoparticles for corrosion protection.

“We have a high standard of quality control for our products, and we manufacture a premium coating solution," says Isolcork manufacturer Pablo Palma. "We buy the best cork from the best producer of cork in the world, which is in the country of Portugal, and we use a unique grain size that we process manually in our manufacturing facility. I can certainly say that making spray cork is like being a master chef with a Michelin-starred restaurant. We are proud of our product, and we will keep it that way for our clients.”

American commercial buildings, especially warehouses, manufacturing, and healthcare facilities, that add Isolcork and meet certain government requirements can also qualify for a tax deduction of up to $5 per square foot, according to Section 179D.

Isolcork maintains a trusted partnership with a specialized tax firm that can build and certify the energy models for commercial buildings under Section 179D tax deduction incentives.

The global green construction is estimated to reach $774 billion by 2030, with a significant compound annual growth rate (CAGR) of 11.8 percent from 2022 to 2032.Texas is the second-largest market in the U.S. for these type of products.

“Our success is due to three worldwide trends in the construction industry," says Isolcork's Mario Palma. "First, environmental entities are looking for natural component materials due to environmental requirements. Second, younger generations who care more about the environment are getting into decision-making positions across industries and they prefer natural products. Third, building owners, no matter what view they have, are looking to save energy and money due to the energy cost increase. Our products are 100 percent aligned with these worldwide trends.”

Companies around the world have been discovering the benefits of Isolcork — one recent example is a large manufacturing facility in Dallas. The estimated energy cost savings in heating and cooling will be between 15 and 20 percent for a standard product solution, plus the estimated tax deduction according to estimation could be equivalent to 70 percent of the total cost of the envelope improvement work.

Isolcork has proven so successful that it even holds the honor of being the first Latin American startup to be part of the Center for Innovation Program at the University of Arizona.

“With the estimated North America demand for Isolcork products being so large, the company is looking for locations and financial support of $10 million to build two manufacturing facilities in Texas and Arizona," says Isolcork USA & Canada country manager Emilio R. Armstrong.

Whether you're looking to invest in Isolcork or simply add it to your structure, the benefits of the sustainable product are immense. Learn more about Isolcork here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings